BIIB : Summary for Biogen Inc. - Yahoo Finance

U.S. Markets closed

Biogen Inc. (BIIB)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
268.53-5.58 (-2.04%)
At close: 4:00PM EDT

268.53 0.00 (0.00%)
After hours: 4:49PM EDT

People also watch
CELGGILDREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close274.11
Open273.91
Bid268.30 x 100
Ask268.51 x 400
Day's Range268.20 - 273.91
52 Week Range223.02 - 333.65
Volume2,431,380
Avg. Volume1,669,595
Market Cap57.99B
Beta0.50
PE Ratio (TTM)15.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen
    Investor's Business Daily48 minutes ago

    Roche Multiple Sclerosis Drug OK Bittersweet For Beleaguered Biogen

    The FDA's approval of a multiple sclerosis drug from Roche is likely to be bittersweet for Biogen, analysts said Wednesday.

  • Reuters8 hours ago

    U.S. approves Roche drug that targets severe form of MS

    Roche's multiple sclerosis (MS) drug Ocrevus won U.S. approval, putting the potential blockbuster back on track after a brief delay and giving a lift to patients with a form of the disease that until now had no approved treatment. The drug, also known as ocrelizumab and administered via infusion, becomes the first U.S. Food and Drug Administration-approved medicine for the primary progressive form of the neurological disease (PPMS). Ocrevus, to have a list price of $65,000 annually, undercutting rival Merck's Rebif by a quarter, is also approved to treat the most common form of MS, known as relapsing-remitting multiple sclerosis (RRMS).

  • Reuters12 hours ago

    UPDATE 2-Roche MS drug Ocrevus approved by FDA after 3-month delay

    The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).